TradeFlare's AI research teams analysed AVIR on 6 market nights between April 27, 2026 and October 1, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| October 1, 2026 | HOLD | $5.21 | — / — | +1.1% | not yet | The stock is in a neutral consolidation phase with no clear directional bias. |
| September 25, 2026 | HOLD | $5.17 | — / — | -0.8% | not yet | The current market and stock setup does not warrant a trade. |
| September 18, 2026 | HOLD | $5.26 | — / — | -3.0% | not yet | The current market regime and the stock's neutral technicals do not support a directional trade. |
| September 17, 2026 | HOLD | $5.15 | $5.92 / $4.79 | -1.7% | not yet | The oversold bounce signal and clinical trial news typically play out over a few weeks. |
| April 28, 2026 | BUY | $5.36 | — / — | +0.4% | -18.5% | No clear bullish catalysts identified. |
| April 27, 2026 | HOLD | $5.47 | — / — | +6.3% | -15.5% | Successful clinical trial results for its HCV/HEV programs. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.